Cargando…
Pfizer-BioNTech and Oxford AstraZeneca COVID-19 vaccine effectiveness and immune response amongst individuals in clinical risk groups
Background COVID-19 vaccines approved in the UK are highly effective in general population cohorts, however, data on effectiveness amongst individuals with clinical conditions that place them at increased risk of severe disease are limited. Methods We used GP electronic health record data, sentinel...
Autores principales: | Whitaker, Heather J., Tsang, Ruby S.M., Byford, Rachel, Andrews, Nick J., Sherlock, Julian, Sebastian Pillai, Praveen, Williams, John, Button, Elizabeth, Campbell, Helen, Sinnathamby, Mary, Victor, William, Anand, Sneha, Linley, Ezra, Hewson, Jacqueline, DArchangelo, Silvia, Otter, Ashley D., Ellis, Joanna, Hobbs, Richard F.D., Howsam, Gary, Zambon, Maria, Ramsay, Mary, Brown, Kevin E., de Lusignan, Simon, Amirthalingam, Gayatri, Lopez Bernal, Jamie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier Ltd on behalf of The British Infection Association.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8720678/ https://www.ncbi.nlm.nih.gov/pubmed/34990709 http://dx.doi.org/10.1016/j.jinf.2021.12.044 |
Ejemplares similares
-
Thrombocytopenic purpura with AstraZeneca but not Pfizer-BioNTech COVID-19 vaccine
Publicado: (2021) -
AstraZeneca and Pfizer-BioNTech COVID-19 vaccines: AEs in South Korea
Publicado: (2021) -
Comparison of antibody responses before and after booster doses with the Pfizer-BioNTech or Oxford–AstraZeneca vaccines in healthcare workers in Thailand
por: Phumisantiphong, Uraporn, et al.
Publicado: (2023) -
Vaccine efficacy against SARS-CoV-2 for Pfizer BioNTech, Moderna, and AstraZeneca vaccines: a systematic review
por: Reynolds, Lia, et al.
Publicado: (2023) -
Quantitative SARS-CoV-2 anti-spike responses to Pfizer–BioNTech and Oxford–AstraZeneca vaccines by previous infection status
por: Eyre, David W., et al.
Publicado: (2021)